Reading the tape
NASDAQ: CYTK
Cytokinetics, Incorporated
Healthcare · Biotechnology
Market Cap
$8.13B
52w High
$70.98
52w Low
$29.31
P/E
-10.27
Volume
2.07M
Outstanding Shares
123.16M
Price vs Fundamentals
Why The Stock Is Moving
Optimism is getting priced inModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 80.12%Revenue (TTM): 376.56%FCF (TTM): -33.77%P/S: 100th pct
What changed
The stock rose 80.12% over the last year. Revenue grew 376.56% over the trailing twelve months. Operating margin moved from -2,902.72% to -695.44%. Free cash flow declined 33.77% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (100th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -695.44% — continued expansion would be needed to justify the premium. Revenue growth of 376.56% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
CEORobert I. Blum
SectorHealthcare
IndustryBiotechnology
Employees498
IPO dateApr 30, 2004
Valuation
Forward P/E—
EV/EBITDA-10.36
Enterprise value$8.03B
Stock splits
Jun 25, 2013↓ Reverse
Every 6 shares became 1
Profitability & growth
Revenue growth4.89%
Gross margin-22.29%▲105.09%vs FY2024
Operating margin-695.44%▲76.04%vs FY2024
ROE119%▼72.67%vs FY2024
Analyst consensus
RatingBuy
Target price$92.50▲40.05%
32
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$1.67 · Revenue est $8.52M
View